H3B-6527
- Generic Name
- H3B-6527
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C29H34Cl2N8O4
- CAS Number
- 1702259-66-2
- Unique Ingredient Identifier
- 4HTE364XIK
- Background
H3B-6527 is under investigation in clinical trial NCT03424577 (A Study to Evaluate the Food-Effect of H3B-6527).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Food-Effect of H3B-6527
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT03424577
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- H3 Biomedicine Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT02834780
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Pennsylsvania - Perelman Cancer Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath